ASK REDCHAT ANYTHING ABOUT ERASCA INC.
Erasca Inc. (NASDAQ: ERAS)
Listen to this Section
$12.26
-1.0100
(
-7.61% )
2.3M
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Naporafenib (pan-RAF inhibitor) w/ trametinibDetailsMelanoma, NRASm melanoma |
Phase 3 |
| Naporafenib (pan-RAF inhibitor) w/ trametinibDetailsRAS Q61X solid tumors, Solid tumor/s |
Phase 1b |
| ERAS-007 w/ encorafenib and cetuximabDetailsCancer, Advanced malignancies, Gastrointestinal stromal tumors, Colorectal cancer , BRAFm Colorectal Cancer |
Phase 1b |
| ERAS-801/EGFR inhibitorDetailsCancer, Glioblastoma |
Phase 1 |
| ERAS-007 + ERAS-601DetailsSolid tumor/s, Cancer |
Failed |
| ERAS-601 (SHP2 inhibitor)DetailsSolid tumor/s, Cancer, Head and neck squamous cell carcinoma |
Failed |
| ERAS-007DetailsNon-small cell lung carcinoma |
Failed |
| Naporafenib (pan-RAF inhibitor) w/ trametinibDetailsSolid tumor/s, RAS Q61X solid tumors |
Phase 1b |
Market Data
|
| Open |
$12.26 |
| Previous Close |
$13.27 |
| Volume |
2.3M |
| Market Cap |
$4.10B |
| Day Range |
$12.20 - $13.56 |
| 52 Week Range |
$1.21 - $24.28 |
| Shares Outstanding |
310.99M |
| Change % |
-7.61% |
| Net Change |
▼ -1.0100 |
| Insider Ownership |
-0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2021 |
| Country | United States |
| Underwriter | J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, Guggenheim Securities, more |
Insider Ownership Transactions
Total Amount Purchased:
-3,127,441.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-06-21 |
Sale |
-137142.00 |
Morris Shannon |
| 2024-06-21 |
Sale |
-60000.00 |
Hambleton Julie |
| 2024-06-21 |
Sale |
-60000.00 |
Casdin Alexander W. |
| 2024-06-21 |
Sale |
-60000.00 |
Bristol James Arthur |
| 2024-06-21 |
Sale |
-632759.00 |
Lim Jonathan E |
| 2024-06-21 |
Sale |
-60000.00 |
Multani Pratik S |
| 2024-06-21 |
Sale |
-60000.00 |
Varney Michael David |
| 2024-06-21 |
Sale |
-160082.00 |
Garner Ebun |
| 2024-06-21 |
Sale |
-60000.00 |
LIU JEAN I |
| 2024-06-21 |
Sale |
-60000.00 |
Start Valerie Denise Harding |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| schedule |
Other |
2 |
Nov 14, 2025 |
| 10-q |
Quarterly Reports |
76 |
Nov 12, 2025 |
| 8-k |
8K-related |
11 |
Nov 12, 2025 |
| 8-k |
8K-related |
11 |
Aug 12, 2025 |
| 10-q |
Quarterly Reports |
77 |
Aug 12, 2025 |
| 4 |
Insider transactions |
1 |
Jun 26, 2025 |
| 4 |
Insider transactions |
1 |
Jun 26, 2025 |
| 4 |
Insider transactions |
1 |
Jun 26, 2025 |
| 4 |
Insider transactions |
1 |
Jun 26, 2025 |
| 8-k |
8K-related |
10 |
Jun 26, 2025 |